Gene Therapy in CVMD

2018-06-30
Price :
Published : Jun-2018
No. of Pages : 80

Gene Therapy in CVMD

Summary

Gene therapies have been a point of discussion during the last several years as a potential curative option for a variety of disease indications. While mainly still in preclinical stages, gene therapy aims to treat or alleviate a disease by genetically modifying the cells of a patient. This report focuses on gene therapies in development across the 8MM for cardiovascular and metabolic disorders, including coronary artery disease, critical limb ischemia, diabetic foot ulcers, and Pompe Disease. In addition, this report provides an assessment of the pipeline, clinical, and commercial landscape of gene therapies in CVMD supplemented with a variety of KOL and payer perspectives.

Scope

This report combines KOL and Payer insights along with data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include –
– Overview of CVMD and Gene Therapies: epidemiology and regulatory oversight
– Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
– Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors
– Market Access: considerations for reimbursement, pricing, and unmet needs
– Market Outlook: competitive assessment and key market events (2018-2025).

Reasons to buy

– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global CVMD gene therapy market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CVMD gene therapy market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Filed in: Biotechnology
Publisher : GlobalData
More Reports
Title Price Buy Now

Biotechnology – Thematic Research

Biotechnology - Thematic Research Summary At its core, biotechnology is harnessing biological and molecular systems to develop products and processes. This report focuses on the most important and fastest growing areas of biotechnology which are its application to health and medicine. It is divided into three areas: agricultural biotechnology, which includes development of genetically modified crops; industrial biotechnology, which includes production of chemicals, paper and textiles; and medical biotechnology which includes the themes covered in this report such as biosimilars and the microbiome. The thematic report also predicts that companies which make the most effective use of the modern data tools are going to be successful while, in the long run, big pharma could be threatened b......
$1950

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027 Summary Amyotrophic Lateral Sclerosis (ALS) is a motor neuron degenerative disease which affects both upper motor neurons (UMN) and lower motor neurons (LMN). It is a progressive disease, with patients becoming increasingly dependent on carers and physicians as time from onset increases, and ultimately, it is fatal. ALS can be split into two origins, hereditary - which is known as FALS (Familial ALS) or idiopathic - known as SALS (sporadic ALS). Currently there are only two drugs on the market that are approved for the treatment of ALS; Sanofi's Rilutek (riluzole) and Mitsubishi Tanabe Pharma's Radicava (edaravone). The drugs were special cases in terms of FDA approval, they did not meet the normal regulatory requi......
$10995

Multiple Sclerosis: Competitive Landscape to 2026

Multiple Sclerosis: Competitive Landscape to 2026 Summary Multiple Sclerosis (MS) is primarily considered an inflammatory demyelinating disorder of the CNS due to a dysfunctional immune system, leading to neurological disability1. The etiology of MS remains unknown; however, it is widely regarded as a complex interaction of genetic susceptibility, dysfunction of the immune system, and environmental factors. This report provides an assessment of the pipeline, clinical, and commercial landscape of MS. Overall, GlobalData expects that new drug approvals will expand the treatment options and drive MS market growth over the next decade (2016-2026). Scope This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the ......
$3495

Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2018

Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2018" provides an overview of Peripheral Neuropathy (Sensory Neuropathy) clinical trials scenario. This report provides top line data relating to the clinical trials on Peripheral Neuropathy (Sensory Neuropathy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Tr......
$2500

Panic Disorders Global Clinical Trials Review, H1, 2018

Panic Disorders Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Panic Disorders Global Clinical Trials Review, H1, 2018" provides an overview of Panic Disorders clinical trials scenario. This report provides top line data relating to the clinical trials on Panic Disorders. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area

The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area Summary GlobalData's "The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area", provides an insight-rich overview of the key events and trends that shaped the industry during 2017. Within each of the major therapeutic areas covered, GlobalData's analysts have identified the most impactful happenings during 2017 - such as product launches and label expansions, losses of patent protection and market exclusivity, and key clinical trial data readouts - and provided expert insight on the implications of each event. For the biopharmaceutical industry, 2017 was marked by noteworthy innovation as well as disappointments across therapy areas, set against a backdrop of remarkable advances in technology in he......
$275

Japan Tissue Engineered – Skin Substitute Procedures Outlook to 2024

Japan Tissue Engineered - Skin Substitute Procedures Outlook to 2024 Summary GlobalData's new report, Japan Tissue Engineered - Skin Substitute Procedures Outlook to 2024, provides key procedures data on the Japan Tissue Engineered - Skin Substitute Procedures. The report provides procedure volumes within market segments - Biologic Skin Substitute Procedures, Synthetic Skin Substitute Procedures and Biosynthetic Skin Substitute Procedures. The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gath......
$2995

United States Tissue Engineered – Skin Substitute Procedures Outlook to 2024

United States Tissue Engineered - Skin Substitute Procedures Outlook to 2024 Summary GlobalData's new report, United States Tissue Engineered - Skin Substitute Procedures Outlook to 2024, provides key procedures data on the United States Tissue Engineered - Skin Substitute Procedures. The report provides procedure volumes within market segments - Biologic Skin Substitute Procedures, Synthetic Skin Substitute Procedures and Biosynthetic Skin Substitute Procedures. The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use o......
$2995

Australia Tissue Engineered – Skin Substitute Procedures Outlook to 2024

Australia Tissue Engineered - Skin Substitute Procedures Outlook to 2024 Summary GlobalData's new report, Australia Tissue Engineered - Skin Substitute Procedures Outlook to 2024, provides key procedures data on the Australia Tissue Engineered - Skin Substitute Procedures. The report provides procedure volumes within market segments - Biologic Skin Substitute Procedures, Synthetic Skin Substitute Procedures and Biosynthetic Skin Substitute Procedures. The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiolo......
$2995

United Kingdom Tissue Engineered – Skin Substitute Procedures Outlook to 2024

United Kingdom Tissue Engineered - Skin Substitute Procedures Outlook to 2024 Summary GlobalData's new report, United Kingdom Tissue Engineered - Skin Substitute Procedures Outlook to 2024, provides key procedures data on the United Kingdom Tissue Engineered - Skin Substitute Procedures. The report provides procedure volumes within market segments - Biologic Skin Substitute Procedures, Synthetic Skin Substitute Procedures and Biosynthetic Skin Substitute Procedures. The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes us......
$2995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy